Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label multicenter study of TP21 injection with TACE for hepatocellular carcinoma
CTR20221306Phase 3Active
- Sponsor
- Beijing Suopu Xingda Pharmaceutical Research
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dicycloplatin in hepatocellular carcinoma (HCC), sponsored by Beijing Suopu Xingda Pharmaceutical Research. Started Aug 2022; status: active.
02
Drugs
dicycloplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221306.